Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators
AssigneeDynogen Pharmaceuticals, Inc.
InventorsMatthew Oliver Fraser, Steven B. Landau, Edward C. Burgard
Life of this patent
Estimating the term…
Abstract
A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.
Claims14
A method for treating a symptom of a non-inflammatory GI tract disorder, comprising administering a therapeutically effective amount of a Cav2.2 subunit calcium channel modulator selected from the group consisting of:
- a. ω-conotoxin GVIA;
- and
- b. ω-conotoxin MVIIA (Ziconotide).
A pharmaceutical composition comprising a Cav2.2 subunit calcium channel modulator in a therapeutically effective amount sufficient to treat a symptom of a non-inflammatory GI tract disorder, wherein said Cav2.2 subunit calcium channel modulator is selected from the group consisting of:
- a. ω-conotoxin GVIA;
- and
- b. ω-conotoxin MVIIA (Ziconotide),
- wherein the pharmaceutical formulation further comprises an additional active agent.
Dependencies are inferred from the claim text.